Adagio Therapeutics anuncia que o ADG20 (adintrevimabe) é o primeiro anticorpo monoclonal a atingir a meta final principal com significância estatística na profilaxia e tratamento pré e pós-exposição à COVID-19, e que pretende solicitar autorização de uso de emergência nos EUA
31 mars 2022 17h01 HE
|
Adagio Therapeutics, Inc.
O risco de COVID-19 sintomático foi reduzido em 71% em comparação com placebo na profilaxia pré-exposição e 75% em comparação com placebo na profilaxia pós-exposição O risco de hospitalização ou...
Adagio Therapeutics Announces ADG20 (adintrevimab) is the First Monoclonal Antibody to Meet Primary Endpoints with Statistical Significance Across Pre- and Post-exposure Prophylaxis and Treatment for COVID-19 and Plans to Seek U.S. Emergency Use Authorization
30 mars 2022 06h30 HE
|
Adagio Therapeutics, Inc.
Risk of symptomatic COVID-19 was reduced by 71% compared to placebo in pre-exposure prophylaxis and 75% compared to placebo in post-exposure prophylaxis Risk of hospitalization or death in...
Adagio Therapeutics, Inc. Announces 2022 Annual Meeting of Stockholders
18 mars 2022 18h33 HE
|
Adagio Therapeutics, Inc.
WALTHAM, Mass., March 18, 2022 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc. (NASDAQ: ADGI) today announced that it will hold its 2022 Annual Meeting of Stockholders virtually at 8:30 a.m. Eastern...
Adagio Therapeutics Announces David Hering Appointed Interim Chief Executive Officer
23 févr. 2022 16h30 HE
|
Adagio Therapeutics, Inc.
WALTHAM, Mass., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc., (Nasdaq: ADGI), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
Adagio Therapeutics Announces ADG20 Development Plans and Pipeline Updates
22 févr. 2022 07h30 HE
|
Adagio Therapeutics, Inc.
Multiple Initiatives Undertaken for ADG20 Assessment, Including Analysis of Clinical Data at 300mg Dose and Exploring Higher Doses of ADG20 in the Clinic Company Pursuing Portfolio of Antibodies in...
Adagio Therapeutics Announces CEO Succession Plan
18 févr. 2022 19h33 HE
|
Adagio Therapeutics, Inc.
WALTHAM, Mass., Feb. 18, 2022 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc. (Nasdaq: ADGI), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
Adagio Therapeutics resume actividad neutralizante de ADG20 contra variantes de SARS-CoV-2 y describe iniciativas para abordar la variante ómicron
13 janv. 2022 19h30 HE
|
Adagio Therapeutics, Inc.
Publicaciones recientes de varios laboratorios independientes muestran que ADG20 tiene actividad neutralizante con potencia comparable a otros anticuerpos que retienen actividad contra la variante...
Adagio Therapeutics、SARS-CoV-2変異株に対するADG20中和活性の概要とオミクロン株に対処するための取り組みを発表
13 janv. 2022 19h30 HE
|
Adagio Therapeutics, Inc.
複数の独立した研究機関による最近の発表によると、ADG20は、オミクロン株に対する活性を保持する他の抗体と同等の効力の中和活性を有する オミクロン株および将来発生する可能性のあるSARS-CoV-2変異株に対応するための複数の取り組みが実施されている マサチューセッツ州ウォルサム発, Jan. 14, 2022 (GLOBE NEWSWIRE) --...
Adagio Therapeutics legt zusammenfassende Ergebnisse zur neutralisierenden Wirkung von ADG20 gegenüber SARS-CoV-2-Varianten vor und stellt Initiativen zur Bekämpfung von Omikron vor
13 janv. 2022 19h30 HE
|
Adagio Therapeutics, Inc.
Aktuelle Veröffentlichungen verschiedener unabhängiger Labore bestätigen, dass die neutralisierende Wirkung von ADG20 mit anderen Antikörpern vergleichbar ist, die die Aktivität gegen Omikron...
Adagio Therapeutics résume l'activité neutralisante de l'ADG20 contre les variants du SARS-CoV-2 et décrit ses initiatives visant à contrer Omicron
13 janv. 2022 19h30 HE
|
Adagio Therapeutics, Inc.
Des publications récentes de plusieurs laboratoires indépendants montrent que l'ADG20 a une activité neutralisante présentant une puissance comparable à d'autres anticorps et qui reste active contre...